Gene: UBE2V2
Official Full Name: ubiquitin conjugating enzyme E2 V2provided by HGNC
Gene Summary: Ubiquitin-conjugating enzyme E2 variant proteins constitute a distinct subfamily within the E2 protein family. They have sequence similarity to other ubiquitin-conjugating enzymes but lack the conserved cysteine residue that is critical for the catalytic activity of E2s. The protein encoded by this gene also shares homology with ubiquitin-conjugating enzyme E2 variant 1 and yeast MMS2 gene product. It may be involved in the differentiation of monocytes and enterocytes. [provided by RefSeq, Jul 2008]
Catalog Number | Product Name | Species | Gene | Passage ratio | Mycoplasma testing | Price |
---|---|---|---|---|---|---|
KO12858 | UBE2V2 Knockout cell line (HeLa) | Human | UBE2V2 | 1:3~1:6 | Negative | Online Inquiry |
KO12859 | UBE2V2 Knockout cell line (HCT 116) | Human | UBE2V2 | 1:2~1:4 | Negative | Online Inquiry |
KO12860 | UBE2V2 Knockout cell line (HEK293) | Human | UBE2V2 | 1:3~1:6 | Negative | Online Inquiry |
KO12861 | UBE2V2 Knockout cell line (A549) | Human | UBE2V2 | 1:3~1:4 | Negative | Online Inquiry |
UBE2V2 Gene Knockout Cell Lines represent a significant advancement in cellular research, specifically designed to study the functional role of the UBE2V2 gene, known for its involvement in the ubiquitin-proteasome system. These cell lines offer researchers a unique platform to investigate the consequences of UBE2V2 deficiency, facilitating a deeper understanding of its contribution to protein homeostasis, DNA repair, and various disease processes, including cancer.
The unique mechanism of these knockout cell lines allows for the specific deletion of the UBE2V2 gene, leading to alterations in cellular signaling pathways and cellular responses to stress. By using CRISPR-Cas9 technology, our UBE2V2 gene knockout cell lines enable precise genomic editing, ensuring that any observed phenotypic changes can be directly attributed to the lack of UBE2V2 expression. This specificity enhances the reliability of experimental outcomes when studying autophagy, inflammatory responses, and tumorigenesis.
Scientifically, these cell lines serve as invaluable tools across research and clinical settings, offering insights into therapeutic targets for diseases where UBE2V2 is implicated. Their application in drug discovery, cancer research, and understanding neurodegenerative diseases exemplifies their versatility, allowing scientists to elucidate new pathways and therapeutic interventions.
Compared to other genetic models, our UBE2V2 knockout cell lines stand out due to their robust background, high reproducibility, and ease of use, facilitating swift integration into existing workflows. This quality ensures reliable results, making them a preferred choice for researchers seeking to validate their hypotheses regarding ubiquitin-related processes.
Ultimately, researchers and clinicians can leverage these knockout cell lines to advance studies in cellular metabolism and proteostasis, leading to breakthroughs that could pave the way for novel therapeutic strategies. Committed to excellence in biological products, our company, with its deep-rooted expertise in genetic engineering, ensures that these UBE2V2 gene knockout cell lines meet the highest standards of quality and reliability, supporting our clients in achieving their research goals.
Please note that all services are for research use only. Not intended for any clinical use.
If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.
There is no product in your cart. |
CD Biosynsis is a leading customer-focused biotechnology company dedicated to providing high-quality products, comprehensive service packages, and tailored solutions to support and facilitate the applications of synthetic biology in a wide range of areas.